OS in MDS patients by disease state. (A) Overall TN patients vs overall R/R patients. The median OS in patients with TN MDS was NR (95% CI, 7.3 to NR) and represented 2 patients (29%) with an event and 5 (71%) who were censored. The median OS in patients with R/R MDS was 16.3 months (95% CI, 3.1-36.6) and represented 12 (80%) with an event and 3 (20%) who were censored. (B) Combination therapy group TN patients vs combination therapy R/R patients. The median OS in patients with TN MDS who received combination OLU + AZA was 26.9 months (95% CI, 7.3 to NR) and represented 2 (40%) with an event and 3 (60%) who were censored. The median OS in patients with R/R MDS who received combination OLU + AZA was 27.5 months (95% CI, 1.5-36.6) and represented 9 (82%) with an event and 2 (18%) who were censored.